Hypnotic drug risks of mortality, infection, depression, and cancer: but lack of benefit.
Level 5 - mechanism / opinion, no new human data
Narrative review of hypnotic drug risks and benefits without systematic search methodology.
PubMed 27303633 · doi:10.12688/f1000research.8729.3
What was done
This was a narrative review summarizing literature on the adverse risks and clinical benefits of hypnotic medications (sleeping pills), alongside non-pharmacological alternatives such as cognitive behavioral therapy for insomnia and bright light treatment.
What was found
No quantitative data, effect estimates, or statistical values are reported in the abstract. The author asserts that hypnotics are associated with excess mortality (including overdose, quiet deaths at night, and suicides), infections, cancer, depression, motor vehicle crashes, falls, other accidents, and withdrawal insomnia. The abstract also states that short-term use (one to two prescriptions) carries greater risk per dose than long-term use, and that recommended doses provide little to no objective increase in sleep while often worsening daytime performance.
Why it matters
This review challenges common prescribing patterns for insomnia by arguing that the risks of hypnotics outweigh their limited objective efficacy relative to safer non-pharmacological interventions.
Limits
The abstract describes an unsystematic narrative review providing no quantitative data, effect sizes, sample sizes, or study selection criteria. Because primary data and specific study methodologies are not detailed, the underlying evidence quality and confounding cannot be evaluated from the abstract.
Cited by
- supports Sleeping pill use is epidemiologically associated with increased risk of all-cause mortality, cancer, and infections such as pneumonia.